Cost–Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer

David Lairson (), Rohan Parikh, Janice Cormier, Wenyaw Chan and Xianglin Du

PharmacoEconomics, 2014, vol. 32, issue 10, 1005-1013

Abstract: FOLFOX appears more effective and cost effective than other strategies for colon cancer treatment of older patients. Results were sensitive to age, with ICERs exhibiting a U-shaped pattern. Copyright Springer International Publishing Switzerland 2014

Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1007/s40273-014-0180-8 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:32:y:2014:i:10:p:1005-1013

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-014-0180-8

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().